blincyto
amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
pediatrica specialist pediapeg polvere trattamento stitichezza 400g
pediatrica specialist srl -
pediatrica specialist uroped integratore alimentare 10 bustine
pediatrica specialist srl -
pediatrica specialist pediavit 400 gocce 15ml
pediatrica specialist srl -
pediatrica idraped integratore alimentare 10 bustine
pediatrica specialist srl -
pediatrica pediasol latte solare spray spf30
pediatrica srl -
pediatrica pediasol spf50 crema solare 125ml
pediatrica srl -
pediatrica specialist graviped nausea 24 chewing gum 1,2g
pediatrica specialist srl -
pediatrica immunoped integratore alimentare 14 bustine
pediatrica srl -